+0.0010  (+0.16%)
Volume (24h): 340.20K Day Range: 0.6221 - 0.6520
Market Cap: 51.97M 52W Range: 0.5500 - 5.68
Apr-02-20 10:24AM Does Assertio Therapeutics, Inc. (NASDAQ:ASRT) Have A Particularly Volatile Share Price?Simply Wall St.
Mar-17-20 03:41PM Wayne-based drug company enters into $17.5M merger dealAmerican City Business Journals
02:15PM Are Shareholders Getting a Fair Deal? Halper Sadeh LLP Investigates the Sale of These Companies – WLTW, TTPH, ASRT, MEETGlobeNewswire
Mar-16-20 10:45PM Assertio Therapeutics Agrees to Merge with Zyla Life Sciences to Create Synergistic Portfolio of Neurology and Non-Opioid Pain ProductsGlobeNewswire
Mar-11-20 05:01AM Assertio Therapeutics Announces Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes Due 2021 and 5.00% Senior Convertible Notes Due 2024GlobeNewswire
Mar-09-20 09:55PM Assertio (ASRT) Reports Q4 Loss, Tops Revenue EstimatesZacks
08:02PM Assertio Therapeutics Announces Fourth-Quarter and Full-Year 2019 Financial ResultsGlobeNewswire
Mar-09-20 06:30AM Assertio Therapeutics, Inc. to Host Earnings CallACCESSWIRE
Mar-08-20 08:14PM The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow ContinuesBenzinga
Mar-02-20 10:30PM Assertio Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results After the Close of Markets on Monday, March 9, 2020GlobeNewswire
Feb-26-20 05:30PM Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out forZacks
Feb-24-20 03:33PM Assertio (ASRT) to Report Q4 Earnings: What's in Store?Zacks
Feb-19-20 01:00PM Assertio Therapeutics Announces Repurchase of Approximately $188.0 Million of its Outstanding Convertible DebtGlobeNewswire
Feb-17-20 11:00AM Did Changing Sentiment Drive Assertio Therapeutics's (NASDAQ:ASRT) Share Price Down A Painful 93%?Simply Wall St.
Feb-14-20 01:23PM The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices OfferingBenzinga
Feb-13-20 09:05PM Assertio Therapeutics Announces Closing of Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 MillionGlobeNewswire
Feb-07-20 12:32PM The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO ResignsBenzinga
Feb-06-20 09:01PM Assertio Therapeutics Announces Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 MillionGlobeNewswire
Feb-04-20 10:45PM Assertio (ASRT) Gains But Lags Market: What You Should KnowZacks
Jan-29-20 10:45PM Assertio (ASRT) Dips More Than Broader Markets: What You Should KnowZacks
Jan-22-20 04:30PM Is ASSERTIO THERAPEUTICS, INC (ASRT) Outperforming Other Medical Stocks This Year?Zacks
Jan-15-20 10:45PM Assertio (ASRT) Stock Sinks As Market Gains: What You Should KnowZacks
Jan-13-20 04:40PM ASRT or PCRX: Which Is the Better Value Stock Right Now?Zacks
12:50PM Assertio Therapeutics Announces Closing of Gralise® Sale to Alvogen and Expects Full-Year 2019 Neurology Franchise Net Sales Above Upper End of Prior GuidanceGlobeNewswire
Jan-09-20 10:45PM Assertio (ASRT) Stock Sinks As Market Gains: What You Should KnowZacks
Jan-08-20 03:18PM Tyme Out-Licenses Cancer Candidate to Eagle Pharma, Stock UpZacks
Jan-07-20 02:51PM Intrexon's Blood Cancer Drug Gets Orphan Drug Status From FDAZacks
02:17PM Catalyst Gives Preliminary Firdapse Estimates & Other UpdatesZacks
Dec-27-19 04:40PM ASRT vs. PCRX: Which Stock Is the Better Value Option?Zacks
Dec-23-19 05:00PM Assertio (ASRT) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks
Dec-19-19 11:40AM Need To Know: Assertio Therapeutics, Inc. (NASDAQ:ASRT) Insiders Have Been Buying SharesSimply Wall St.
Dec-13-19 08:07PM Hedge Funds Are Crazy About Assertio Therapeutics, Inc. (ASRT)Insider Monkey
01:39PM Assertio to Divest Shingles Pain Drug to Alvogen for $127.5MZacks
Dec-12-19 12:50PM Assertio Therapeutics Announces Sale of Gralise® for Total Transaction Value of $127.5 MillionGlobeNewswire
Dec-10-19 04:40PM ASRT vs. PCRX: Which Stock Should Value Investors Buy Now?Zacks
Nov-26-19 07:29PM Assertio Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare ConferenceGlobeNewswire
Nov-13-19 05:58PM Assertio Therapeutics to Present at the 2019 Stifel Healthcare ConferenceGlobeNewswire
Nov-07-19 04:26PM PDL BioPharma (PDLI) Q3 Earnings Beat, LENSAR Drives SalesZacks
12:45AM Assertio (ASRT) Surpasses Q3 Earnings EstimatesZacks
Nov-06-19 09:05PM Assertio Therapeutics Announces Third-Quarter 2019 ResultsGlobeNewswire
Nov-04-19 11:05AM How Much Did Assertio Therapeutics, Inc.'s (NASDAQ:ASRT) CEO Pocket Last Year?Simply Wall St.
Oct-30-19 10:35PM Ceridian HCM Holding, BJ's Wholesale Club Holdings Set to Join S&P MidCap 400; Oceaneering International, Covetrus to Join S&P SmallCap 600PR Newswire
02:34PM Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out forZacks
Oct-23-19 01:05PM Assertio Therapeutics to Report Third-Quarter 2019 Financial Results After the Close of Markets on Wednesday, November 6, 2019GlobeNewswire
Oct-22-19 11:51AM The Daily Biotech Pulse: Biogen Alzheimer's Program Back On Track, Novartis Reports Strong Quarter, Takeda In-Licenses Autoimmune Disorder DrugBenzinga
Oct-21-19 01:05PM Assertio Therapeutics Provides Regulatory Update on Long-Acting CosyntropinGlobeNewswire
Oct-13-19 08:33PM The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma EarningsBenzinga
Oct-05-19 01:54PM How Does Assertio Therapeutics, Inc. (NASDAQ:ASRT) Affect Your Portfolio Volatility?Simply Wall St.
Sep-30-19 04:35PM Assertio Therapeutics Announces Appointment of Dr. David Wheadon to its Board of DirectorsGlobeNewswire
Sep-26-19 12:00PM Assertio Therapeutics to Present at the Annual Cantor Fitzgerald Global Healthcare ConferenceGlobeNewswire
Assertio Therapeutics, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of Cebranopadol for the treatment of chronic nociceptive and neuropathic pain. It has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc.; and a license agreement with Janssen Pharmaceuticals, Inc. based on its proprietary Acuform gastroretentive drug delivery technology. The company sells its products to wholesalers and retail pharmacies. The company was formerly known as Depomed Inc. and changed its name to Assertio Therapeutics, Inc. in August 2018 Assertio Therapeutics, Inc. was founded in 1995 and is headquartered in Lake Forest, Illinois.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)